PMA device
VISITAG SURPOINT External Processing Unit (EPU)
Biosense Webster, Inc. · Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Flutter (OAD, Class III) · First FDA decision Jun 1, 2018, newest Jun 30, 2026Atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
1
Naming "VISITAG SURPOINT External"
MAUDE reports
0
Brand "VISITAG SURPOINT External", since 2015
PubMed studies
0
Mentioning "VISITAG SURPOINT External"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VISITAG SURPOINT External Processing Unit (EPU)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
P030031-S143 · Decided Jun 30, 2026 · 90 days after receipt · Normal 180 Day Track
Device type: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter (OAD) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
- Percutaneous minimally invasive fusion/stabilization of the sacroiliac joint for the treatment of back painLocal determinationIn effectL36000WPS Insurance CorporationUpdated May 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "VISITAG SURPOINT External", any status and sponsor, newest update first.
Biosense Webster, Inc.Public (JNJ)
NCT03624881 · 333 participants · Start Sep 4, 2018 · Primary completion Jun 28, 2021
Device: Catheter ablation with EPU · For: Paroxysmal Atrial Fibrillation
Sites: Birmingham, Alabama; Huntsville, Alabama; Little Rock, Arkansas · 41 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VISITAG SURPOINT External", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OAD
3,979 reports: 1,924 malfunction, 1,908 injury, 137 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Johnson & Johnson Surgical Vision, Inc.
Z-0169-2023 · Started Sep 7, 2022 · Posted by FDA Nov 2, 2022
Reason given: Manufacturing error resulted in potential contamination of Bi-Directional navigation catheter irrigation path with cellulose fibers that can cause 1) Failure of initial flushing inspection, 2) Insufficient irrigation causing catheter tip temperature increase, limiting the ability to deliver ablation, or 3) particles...
Cause as FDA categorized it: Process control · Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Flutter (OAD)
7 more recall records with a free account
Published research
The most relevant PubMed records for "VISITAG SURPOINT External"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OAD.
- Blazer Open-Irrigated Ablation CatheterBoston Scientific Corp · PMA 2025
- Blazer II XP Cardiac Ablation Catheter and CableBoston Scientific · PMA 2025
- FlexAbility Ablation Catheter, Sensor EnabledAbbott Medical · PMA 2025
- Therapy Dual 8 Catheter,therapy 8MM Thermistor Ablation CatheterIrvine Biomedical,Inc.(Ibi) · PMA 2016
- THERMOCOOL SMARTTOUCH® SF CatheterBiosense Webster, Inc. · PMA 2026
- Therapy Cool Path DuoAbbott Medical · PMA 2020
- Safire TX Ablation CatheterIrvine Biomedical,Inc.(Ibi) · PMA 2022
- Therapy Cool PathIrvine Biomedical, Inc. · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.